Abstract: A method for treating a subject suffering from a neurodegenerative disease includes administering at least one triterpenoid which can be obtained from Hedera helix. A method for treating a subject suffering from a neurodegenerative disease includes administering an effective amount of a Hedera helix extract which comprises the triterpenoid. The neurodegenerative disease is preferably but not exclusively Parkinson's disease or Huntington's disease. Methods for extracting the triterpenoid from Hedera helix and a method for inducing autophagy in cells by contacting them with the triterpenoid are also provided. The triterpenoid allows an exceptional induction of autophagy, in particular a significant reduction of the protein level of mutant huntingtin, a significant reduction of the protein level of A53T ?-synuclein, a significant inhibition of the oligomerization of ?-synuclein and a significant inhibition of the inclusion formation of huntingtin via the AMPK-mTOR dependent autophagy inducing pathway.

Abstract: The present disclosure is applicable to the field of communications device technologies is directed to a duplexer and a communications system having the duplexer. The duplexer includes a body, where an input port and an output port are disposed on the body, a cavity is disposed on the body, a dielectric resonator is disposed in the cavity, the input port is connected to an input-end coupling plate disposed opposite to the dielectric resonator, the output port is connected to an output-end coupling plate disposed opposite to the dielectric resonator, a tuning screw is connected to the body, and a central axis of the dielectric resonator misaligns with a central axis of the cavity. The communications system includes the duplexer.

Abstract: A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.

Abstract: A method for inhibiting the expression and/or functional activity of an ABC transporter protein in a subject suffering from a disorder associated with an overexpression of the ABC transporter protein includes administrating a cobalt-polypyridyl complex to the subject. A method for inhibiting the expression and/or functional activity of an ABC transporter in cells includes contacting the cells with an effective amount of the cobalt-polypyridyl complex.

Abstract: A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.

Abstract: A ultraviolet and infrared absorbing polyvinyl butyral film is disclosed which is comprised of copper chalcogenide nanoparticles and oxide nanoparticles. The polyvinyl butyral film has a visible transmittance greater than 75%, at least 50% absorption between 780 and 1400 nm, around 100% absorption beyond 1400 nm, and at least 85% absorption in the UV region. Also disclosed is a laminate comprising one or more substrates, a polymeric matrix disposed on or between the one or more substrates, and copper chalcogenide nanoparticles dispersed in the polymeric matrix.

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

Abstract: A non-destructive method of measuring tear lines formed in a surface of a resilient automotive trim panel configured for overlaying an inflatable safety device includes the steps of periodically selecting a trim panel for testing from a flow of in-process trim panels, mounting the selected trim panel to a mounting jig configured to support a region of the selected trim panel adjacent a tear line and to temporarily splay said selected trim panel to expose opposed edges forming at least a portion of the tear line, scanning a 3D image of the opposed edges, storing said 3D image as data in an associated processor, and removing the selected trim panel from the mounting jig. The mounting jig includes a base forming upwardly facing longitudinally elongated converging guide surfaces intersecting at a common apex, and a cover member forming downwardly facing longitudinally elongated converging support surfaces intersecting at a common apex.

Abstract: An electronic apparatus production system is disclosed. The electronic apparatus production system comprises a transmission rail in the form of a substantially closed loop, a plurality of storage trays circulating on the transmission rail, each of the storage trays comprising a plurality of holding portions to hold a plurality of components with different shapes, an automatic distributor configured to mount the components with different shapes on respective holding portions, and an automatic assembler configured to grip the components on the storage tray.

Abstract: An automatic distributor is disclosed. The automatic distributor comprises a base, a storage device mounted on the base to store a plurality of components with different shapes thereon, a recognition device configured to recognize the components stored on the storage device, and a pickup device configured to pick up the components based on a recognition result of the recognition device.

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.